| Mark D Morrow, AA | |
|
6161 S Yale Ave, Tulsa, OK 74136-1902 | |
| (918) 494-0612 | |
| Not Available |
| Full Name | Mark D Morrow |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology Assistant |
| Experience | 31 Years |
| Location | 6161 S Yale Ave, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336143817 | NPI | - | NPPES |
| 43398100 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | (* (Not Available)) | Secondary |
| 367H00000X | Anesthesiologist Assistant | 11 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Francis Hospital, Inc | Tulsa, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Associated Anesthesiologists, Inc. | 7911989017 | 111 |
News Archive
Unigene Laboratories, Inc. announced today that the Company is accelerating the development of its lead proprietary anorexigenic peptide, UGP281.
The 2019 3Rs prize has been jointly awarded to Dr Francesca Nunn and Dr Marta Shahbazi for papers describing research that reduces the number of chickens and mice respectively. The 3Rs prize is awarded by the NC3Rs and sponsored by GSK.
After phase 1 results of Seattle Children's Pediatric Leukemia Adoptive Therapy trial have shown T-cell immunotherapy to be effective in getting 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia into complete initial remission, researchers have now opened a first-in-human clinical trial aimed at reducing the rate of relapse after the therapy, which is about 50 percent.
An international research collaboration led by UCL scientists has developed ways to improve the quality and accuracy of information harvested from epigenome sequencing datasets in two new research papers published jointly in Nature Biotechnology and Nature Communications today. According to the studies, epigenome sequencing technologies can allow for more comprehensive analysis of cancers - a key component in the development of targeted approaches to combat cancer.
› Verified 4 days ago
| Entity Name | Associated Anesthesiologists, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891733598 PECOS PAC ID: 7911989017 Enrollment ID: O20040603000292 |
News Archive
Unigene Laboratories, Inc. announced today that the Company is accelerating the development of its lead proprietary anorexigenic peptide, UGP281.
The 2019 3Rs prize has been jointly awarded to Dr Francesca Nunn and Dr Marta Shahbazi for papers describing research that reduces the number of chickens and mice respectively. The 3Rs prize is awarded by the NC3Rs and sponsored by GSK.
After phase 1 results of Seattle Children's Pediatric Leukemia Adoptive Therapy trial have shown T-cell immunotherapy to be effective in getting 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia into complete initial remission, researchers have now opened a first-in-human clinical trial aimed at reducing the rate of relapse after the therapy, which is about 50 percent.
An international research collaboration led by UCL scientists has developed ways to improve the quality and accuracy of information harvested from epigenome sequencing datasets in two new research papers published jointly in Nature Biotechnology and Nature Communications today. According to the studies, epigenome sequencing technologies can allow for more comprehensive analysis of cancers - a key component in the development of targeted approaches to combat cancer.
› Verified 4 days ago
| Entity Name | Osh Aai Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205170461 PECOS PAC ID: 4587818729 Enrollment ID: O20130216000056 |
News Archive
Unigene Laboratories, Inc. announced today that the Company is accelerating the development of its lead proprietary anorexigenic peptide, UGP281.
The 2019 3Rs prize has been jointly awarded to Dr Francesca Nunn and Dr Marta Shahbazi for papers describing research that reduces the number of chickens and mice respectively. The 3Rs prize is awarded by the NC3Rs and sponsored by GSK.
After phase 1 results of Seattle Children's Pediatric Leukemia Adoptive Therapy trial have shown T-cell immunotherapy to be effective in getting 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia into complete initial remission, researchers have now opened a first-in-human clinical trial aimed at reducing the rate of relapse after the therapy, which is about 50 percent.
An international research collaboration led by UCL scientists has developed ways to improve the quality and accuracy of information harvested from epigenome sequencing datasets in two new research papers published jointly in Nature Biotechnology and Nature Communications today. According to the studies, epigenome sequencing technologies can allow for more comprehensive analysis of cancers - a key component in the development of targeted approaches to combat cancer.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark D Morrow, AA 6839 S Canton Ave, Tulsa, OK 74136-3402 Ph: (918) 494-0612 | Mark D Morrow, AA 6161 S Yale Ave, Tulsa, OK 74136-1902 Ph: (918) 494-0612 |
News Archive
Unigene Laboratories, Inc. announced today that the Company is accelerating the development of its lead proprietary anorexigenic peptide, UGP281.
The 2019 3Rs prize has been jointly awarded to Dr Francesca Nunn and Dr Marta Shahbazi for papers describing research that reduces the number of chickens and mice respectively. The 3Rs prize is awarded by the NC3Rs and sponsored by GSK.
After phase 1 results of Seattle Children's Pediatric Leukemia Adoptive Therapy trial have shown T-cell immunotherapy to be effective in getting 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia into complete initial remission, researchers have now opened a first-in-human clinical trial aimed at reducing the rate of relapse after the therapy, which is about 50 percent.
An international research collaboration led by UCL scientists has developed ways to improve the quality and accuracy of information harvested from epigenome sequencing datasets in two new research papers published jointly in Nature Biotechnology and Nature Communications today. According to the studies, epigenome sequencing technologies can allow for more comprehensive analysis of cancers - a key component in the development of targeted approaches to combat cancer.
› Verified 4 days ago
Christopher Vincent Pollio, AA-C Anesthesiologist Assistant Medicare: Not Enrolled in Medicare Practice Location: 6161 S Yale Ave, Tulsa, OK 74136 Phone: 918-494-2200 | |
Trayston Frazier, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1923 S Utica Ave, Tulsa, OK 74104 Phone: 187-775-8169 | |
Alexandra Millard, Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 1923 S Utica Ave, Tulsa, OK 74104 Phone: 918-744-3131 | |
Tylor Charles O'neill, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1923 S Utica Ave, Tulsa, OK 74104 Phone: 918-744-3131 | |
Tricia L Vowell, AA-C Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1923 S Utica Ave, Tulsa, OK 74104 Phone: 918-744-3118 Fax: 918-744-2946 | |
Hannah Chadick, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 1923 S Utica Ave, Tulsa, OK 74104 Phone: 918-744-2345 |